CagriSema FDA Approval Status: Not Approved Yet — FDA Decision Expected Q4 2026
Published:
·Last verified: May 22, 2026The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Some links on this page are affiliate links and may earn us a commission. That doesn’t change CagriSema’s regulatory status — it’s not FDA approved or available yet — and it doesn’t change our editorial recommendations.
Quick status snapshot — verified May 22, 2026
| CagriSema status item | Current answer |
|---|---|
| FDA approved? | ❌ No |
| FDA application filed? | ✅ Yes — December 18, 2025 |
| Expected U.S. FDA decision | Q4 2026 (per Novo Q1 2026 investor materials) |
| Available by prescription? | ❌ No |
| Legal compounded version? | ❌ No — FDA says cagrilintide cannot be compounded |
| Price known? | ❌ No — not announced |
| PDUFA target date confirmed? | Not publicly confirmed |
| Best step if you want treatment now | Compare FDA-approved GLP-1 options with a licensed clinician |
CagriSema FDA approval status: not FDA approved. Novo Nordisk filed its FDA application for CagriSema on December 18, 2025, and Novo’s Q1 2026 investor presentation lists an expected U.S. FDA decision in Q4 2026. An application filed is not the same as a drug approved.
That’s the answer. If you came here to find out whether you can get CagriSema right now — you can’t. Not legally, not safely, not at any U.S. pharmacy. If you want treatment now, the better move is to look at GLP-1 medications that are already FDA-approved. We’ll walk you through both paths below.
What’s on this page
- Is CagriSema FDA approved?
- Timeline to approval and availability
- Can you buy CagriSema now?
- Can CagriSema be compounded?
- What Novo submitted for
- REDEFINE trial data (full table)
- REDEFINE 4 — the Zepbound head-to-head
- CagriSema vs Wegovy vs Zepbound
- Should you wait or start now?
- FDA-approved alternatives available now
- How much will CagriSema cost?
- Safety and side effects (trial data)
- How we verified this page
- FAQ (17 questions)
- The bottom line
Is CagriSema FDA Approved?
No. CagriSema is not FDA approved.
CagriSema is not FDA approved or commercially available in the United States as of May 22, 2026. Novo Nordisk submitted its New Drug Application — the formal request for FDA approval — on December 18, 2025. Novo says the FDA is expected to review the application in 2026. An application filed is not the same as a drug approved.
What “FDA application filed” actually means
When Novo Nordisk filed its NDA in December 2025, it submitted thousands of pages of clinical trial data, manufacturing details, proposed labeling, and safety information for the FDA to review. The FDA then decides whether to accept the application for review (which typically takes about 60 days). Once accepted, the agency sets a target decision date called a PDUFA date. Standard reviews run about 10 months. Priority reviews run about 6 months.
As of May 22, 2026, no public PDUFA target date or priority-review status has been confirmed for CagriSema. Both of those facts could change at any time — which is why we re-verify this page on a regular cadence.
What still has to happen before patients can get CagriSema
FDA continues its review of Novo's submission.
FDA issues a decision — approval, a Complete Response Letter asking for more information, or a partial approval with label limitations.
If approved, FDA-approved prescribing information (the label) becomes public.
Novo Nordisk announces launch timing, supply availability, and U.S. pricing.
Pharmacies stock the product and prescribers begin writing prescriptions under the approved label.
Even when a drug is approved, real-world access can lag the approval date. FDA approval, pharmacy stocking, supply, and payer coverage are separate steps. We’ll update this page after any approval, label, and payer-policy changes.
When Could CagriSema Be Approved or Available in the U.S.?
Short answer
Novo’s Q1 2026 investor presentation lists an expected U.S. FDA decision in Q4 2026 — roughly October through December 2026. If approved on that timeline, Novo has guided toward a commercial launch in late 2026 or early 2027. None of those dates are guaranteed.
| Date | Milestone | Source / type |
|---|---|---|
| 2018 | Cagrilintide enters early clinical development at Novo Nordisk | Novo Nordisk pipeline disclosures |
| Aug 2022 | Phase 2 CagriSema data — 15.6% weight loss in overweight patients with type 2 diabetes | Novo Nordisk Phase 2 readout |
| 2023 | REDEFINE 1, REDEFINE 2, and REIMAGINE Phase 3 trials launched | ClinicalTrials.gov |
| Dec 20, 2024 | REDEFINE 1 topline: 22.7% weight loss at 68 weeks (efficacy estimand) | Novo Nordisk press release |
| Jun 22, 2025 | REDEFINE 1 full data published in The New England Journal of Medicine; presented at ADA Scientific Sessions | NEJM / PubMed (40544433) |
| Jun 24, 2025 | REDEFINE 2 (T2D population) published in NEJM | NEJM / PubMed (40544432) |
| Nov 6, 2025 | Cardiovascular post-hoc from REDEFINE 1 presented at ObesityWeek; published in Hypertension | Peer-reviewed publication |
| Dec 18, 2025 | Novo Nordisk submits NDA to FDA for chronic weight management | Novo Nordisk press release — NDA filing |
| Feb 23, 2026 | REDEFINE 4 head-to-head vs Zepbound: CagriSema 23.0% vs Zepbound 25.5% — missed non-inferiority endpoint | Novo Nordisk press release |
| Q2 2026 (planned) | High-dose CagriSema phase 3b trial expected to initiate, per Novo Q1 2026 investor presentation | Novo investor materials |
| Q4 2026 (expected) | FDA decision expected, per Novo Q1 2026 investor materials | Novo investor materials |
| Late 2026 / early 2027 | Possible commercial launch if approved (editorial projection based on Novo guidance) | Editorial projection |
| H1 2027 (planned) | REDEFINE 11 long-duration data expected | Novo investor materials |
Why “Q4 2026” doesn’t mean “available in Q4 2026”
An FDA decision is one event. A commercial launch is a different event. Insurance coverage is a third event. Affordable cash-pay access is a fourth event. These can be separated by months.
There’s an added complication: CagriSema uses a dual-chamber pen device that’s more mechanically complex than current GLP-1 pens. Supply at launch is a real question mark.
Our editorial access forecast
Mid-2027 through 2028 for broad, ordinary-patient access — depending on approval timing, launch, supply, and payer adoption. This is not a verified launch date; it’s our editorial read on the realistic path from FDA decision to your pharmacy.
Can You Buy CagriSema Right Now?
No — and any site that says otherwise is a red flag.
There is no legitimate way to buy FDA-approved CagriSema in the United States today, because FDA-approved CagriSema doesn’t exist yet. If you see “CagriSema for sale” online, “compounded CagriSema,” “research-use cagrilintide,” or anything similar, treat it as a red flag — not an early-access loophole.
The FDA has issued specific warnings about unapproved GLP-1 products sold online. These products can be counterfeit, improperly stored, mislabeled, contaminated, or dosed wrong.
Red flags to watch for
| What you might see online | Why it’s a red flag | What to do |
|---|---|---|
| "Buy CagriSema now" | CagriSema is not FDA approved or commercially available — period | Check Drugs@FDA for approval status |
| "Compounded CagriSema" | FDA has said cagrilintide cannot be used in compounding under federal law | Ask the clinic for the legal basis in writing; verify pharmacy license |
| "Research-use cagrilintide" or "research peptide" | Research chemicals aren't approved as medications for humans | Do not self-administer |
| "No prescription needed" | Any GLP-1-class medication should require clinical evaluation | Avoid entirely |
| "Same as CagriSema, just cheaper" | A non-approved product is not the same as an FDA-approved one | Treat the claim as marketing, not science |
| "Pre-order CagriSema before launch" | Novo Nordisk does not sell directly to consumers and has not announced any pre-order program | Likely a scam |
| Overseas pharmacy "early access" | Importing unapproved medications for personal use carries legal and safety risk | Use FDA BeSafeRx to check pharmacy legitimacy |
Legal access matrix
| Path | Available now? | Why or why not |
|---|---|---|
| FDA-approved CagriSema | ❌ No | FDA review ongoing; no approval yet |
| Clinical trial enrollment | ⚠️ Limited | Only if a trial is currently recruiting and you meet eligibility criteria — check ClinicalTrials.gov |
| Compounded CagriSema | ❌ No | FDA says cagrilintide cannot be used in compounding under federal law |
| "Research peptide" cagrilintide | ❌ Not as a medication | Research chemicals are not prescription drugs and should not be self-administered |
| Overseas pharmacy import | ❌ No legal personal-use path | Safety and legal risk; FDA does not approve these channels |
About clinical trial access
Clinical trial enrollment is the one legitimate way some patients have received CagriSema — and it’s different from buying the drug. Most of the major CagriSema trials (REDEFINE 1, 2, and 4; REIMAGINE 2) are now closed to enrollment. REDEFINE 11 is ongoing as of May 2026, and Novo’s Q1 2026 investor materials listed initiation of a phase 3b high-dose CagriSema trial as expected in Q2 2026. ClinicalTrials.gov is the official U.S. registry where you can check current enrollment status by searching “CagriSema.”
Wanted CagriSema and just learned you can’t have it yet?
Get your personalized FDA-approved GLP-1 action plan. 60 seconds, no email required.
Can CagriSema or Cagrilintide Be Compounded?
No — and this is the section most CagriSema articles skip.
The FDA has said cagrilintide — the new active ingredient in CagriSema — cannot be used in pharmacy compounding under federal law, and that it has not been found safe and effective for any condition. A “compounded CagriSema” is not a legal substitute for an FDA-approved one, and it’s not the same situation as past compounded semaglutide or tirzepatide.
Why cagrilintide is different from semaglutide
Compounded semaglutide was widely offered through telehealth clinics during the Wegovy and Ozempic shortages of 2023–2024. That created the (incorrect) impression that any new GLP-1 drug could be compounded the same way. With CagriSema, that’s not true.
Semaglutide has been FDA-approved since 2017. Even during the compounding controversy, the active ingredient itself had years of FDA-reviewed safety data behind it. Cagrilintide does not. It’s a brand-new molecule that has never been FDA-approved for any condition. The FDA has explicitly said cagrilintide cannot be used in compounding, which closes off the path that some clinics tried to use with semaglutide.
Language guide — accurate vs. misleading statements
Accurate, defensible statements
- “CagriSema is investigational.”
- “CagriSema is not FDA approved yet.”
- “CagriSema is not commercially available.”
- “FDA says cagrilintide cannot be used in compounding.”
- “FDA-approved GLP-1 options should be discussed with a licensed clinician.”
Statements to push back on
- “Compounded CagriSema is the same thing.”
- “You can get the active ingredients now.”
- “CagriSema alternatives are clinically equivalent.”
- “CagriSema is basically available if you know where to look.”
Questions to ask any clinic that mentions CagriSema
- Are you claiming to offer FDA-approved CagriSema? (If yes, that’s not currently possible.)
- Are you using cagrilintide in any formulation?
- What is the legal basis for that?
- Which licensed pharmacy is compounding the product, and can you provide their credentials?
- Is this for research use only? (If yes, it shouldn’t be administered to patients.)
- Can you provide all of this in writing on company letterhead?
Honest clinics will answer these directly. Anyone hedging is not the place to get medical care.
What Did Novo Nordisk Actually Submit to the FDA For?
Short answer
Novo submitted CagriSema for chronic weight management in adults with obesity, and adults who are overweight with at least one weight-related comorbidity, used together with a reduced-calorie diet and increased physical activity. The submission was based on the REDEFINE 1 and REDEFINE 2 Phase 3 trials.
The proposed patient population
- Adults with obesity (typically BMI ≥ 30)
- Adults who are overweight (BMI ≥ 27) with at least one weight-related medical condition
- Used as an addition to a reduced-calorie diet and increased physical activity
Is CagriSema also being submitted for type 2 diabetes?
Not in this submission. Novo’s REIMAGINE program is studying CagriSema in type 2 diabetes, but the diabetes filing is a separate regulatory path that hasn’t been submitted yet. Novo has said it will approach authorities about the T2D regulatory pathway after additional REIMAGINE 1 and REDEFINE 3 data. For readers with type 2 diabetes: plan around currently FDA-approved options if you need diabetes treatment now.
Why label details matter for you
The FDA-approved label will determine:
- Who can be legally prescribed CagriSema
- The starting dose and how it’s increased
- Contraindications (conditions that rule out use)
- Required monitoring (lab work, follow-ups)
- Warnings (side effects to watch for)
- How insurance plans will categorize coverage
Until the label is published, anyone making detailed claims about who can take CagriSema or how it’ll be dosed in practice is guessing.
What Clinical Trial Data Supports the CagriSema FDA Application?
Short answer
Novo’s NDA is built on two main trials: REDEFINE 1 (CagriSema in adults with obesity but no diabetes — 22.7% mean weight loss at 68 weeks under the efficacy estimand) and REDEFINE 2 (CagriSema in adults with obesity plus type 2 diabetes — -13.7% body-weight change versus -3.4% on placebo under the treatment-policy estimand). Both were published in The New England Journal of Medicine in June 2025.
| Trial | Population | Duration | Key result | Estimand | Role in NDA |
|---|---|---|---|---|---|
| REDEFINE 1 | Obesity, no diabetes (~3,417 participants) | 68 wks | CagriSema 22.7% vs placebo 2.3% | Efficacy estimand — NEJM Jun 2025 | Primary basis of NDA |
| REDEFINE 2 | Obesity + type 2 diabetes (~1,200 participants) | 68 wks | CagriSema -13.7% vs placebo -3.4% | Treatment-policy estimand — NEJM Jun 2025 | Supportive in NDA |
| REDEFINE 4 | Obesity, head-to-head vs Zepbound (809 participants) | 84 wks | CagriSema 23.0% vs Zepbound 25.5% — missed non-inferiority | Efficacy estimand — Novo Feb 23, 2026 release | Not in NDA — read out after filing |
| REDEFINE 11 | Obesity, longer duration, higher dose | Longer than REDEFINE 1 | Data expected H1 2027 | Ongoing | Future label expansion |
| REIMAGINE 2 | Type 2 diabetes, inadequate metformin control (2,728 participants) | 68 wks | CagriSema: 14.2% weight loss, 1.91 pp HbA1c reduction vs semaglutide 2.4 mg: 10.2% weight loss, 1.76 pp HbA1c reduction | Efficacy estimand — Novo REIMAGINE 2 release | Future T2D filing (separate) |
A quick note on “estimands” — why you see two numbers from the same trial
Efficacy estimand (22.7%)
What the effect would be if everyone stayed on treatment and didn’t take other weight-loss drugs. The idealized scenario.
Treatment-policy estimand (20.4%)
What the effect was across all participants, including people who stopped treatment or switched. Closer to real-world result.
In REDEFINE 1, both are valid — they answer different questions. When comparing CagriSema to other GLP-1s, make sure you’re comparing the same estimand. Otherwise the comparison is misleading.
Safety and tolerability from the trials
The most common side effects reported with CagriSema were gastrointestinal — nausea, vomiting, diarrhea, and constipation — almost all mild to moderate, and most diminished over time.
| Trial | CagriSema discontinuations | Placebo discontinuations |
|---|---|---|
| REDEFINE 1 | 5.9% | 3.5% |
| REDEFINE 2 (T2D) | 8.4% | 3.0% |
Cardiovascular signal worth noting
In a post-hoc analysis from REDEFINE 1, CagriSema reduced systolic blood pressure by 10.9 mmHg versus 8.8 mmHg for semaglutide alone and 2.1 mmHg for placebo. Nearly 4 in 10 participants on blood-pressure medication were able to reduce or stop those medications during the trial. This is exploratory, hypothesis-generating data — not an approved clinical claim — but it’s a real signal that future cardiovascular outcomes work (including REDEFINE 3) is being designed around.
REDEFINE 4 — What the Zepbound Head-to-Head Result Really Means
Short answer
On February 23, 2026, CagriSema (23.0%) did not meet its primary endpoint of being non-inferior to Zepbound (tirzepatide, 25.5%) in the 84-week REDEFINE 4 head-to-head trial. Zepbound won. That said, CagriSema’s 23% weight loss is still a strong absolute result. Crucially, Novo’s obesity NDA was filed two months before REDEFINE 4 read out, and was based on REDEFINE 1 and REDEFINE 2. The head-to-head loss is primarily a commercial issue, not a regulatory one.
| Estimand | CagriSema | Zepbound | Difference |
|---|---|---|---|
| Efficacy estimand (idealized adherence) | 23.0% | 25.5% | -2.5 pp |
| Treatment-regimen estimand (real-world) | 20.2% | 23.6% | -3.4 pp |
The honest damaging admission
CagriSema did not beat Zepbound. If you’re asking “which GLP-1 produces the most weight loss” based on the data that exists today, the answer is tirzepatide, not CagriSema. If raw weight-loss percentage is your single most important factor, Zepbound is the more proven choice right now — it’s FDA-approved, widely available, has comparable trial data, and won the head-to-head.
Why REDEFINE 4 does not directly block FDA approval
The FDA does not require new drugs to beat their competitors. The FDA requires drugs to demonstrate substantial evidence of safety and effectiveness for the proposed use — typically against placebo or existing standard of care. CagriSema produced 22.7% weight loss versus 2.3% on placebo in REDEFINE 1. That’s overwhelming on the standard the FDA actually applies.
The realistic risks to FDA approval for CagriSema are:
- A Complete Response Letter requesting additional data
- Manufacturing or facility issues with the dual-chamber pen device
- Label limits narrowing the approved population
- An Advisory Committee meeting (rare for established mechanisms)
Our editorial assessment: CagriSema has a credible path to approval on or near the Q4 2026 decision window, but approval is not guaranteed.
Is CagriSema Better Than Wegovy or Zepbound?
Short answer
In REDEFINE 1, CagriSema produced more mean weight loss than semaglutide 2.4 mg alone. In REDEFINE 4, CagriSema produced less mean weight loss than tirzepatide 15 mg. But CagriSema is not approved or available — it’s not a current choice, it’s a future option.
| Medication | Trial | Mean weight loss | Duration | FDA status (May 2026) |
|---|---|---|---|---|
| CagriSema | REDEFINE 1 (efficacy estimand) | 22.7% | 68 weeks | Not approved — under FDA review |
| CagriSema | REDEFINE 4 (vs Zepbound, efficacy estimand) | 23.0% | 84 weeks | Not approved — under FDA review |
| Zepbound (tirzepatide) | REDEFINE 4 (head-to-head vs CagriSema) | 25.5% | 84 weeks | FDA-approved ✅ |
| Zepbound (tirzepatide) | SURMOUNT-5 (head-to-head vs semaglutide) | ~20% | 72 weeks | FDA-approved ✅ |
| Wegovy (semaglutide) | SURMOUNT-5 (head-to-head vs tirzepatide) | ~14% | 72 weeks | FDA-approved ✅ |
| Wegovy (semaglutide) | STEP-1 | ~15% | 68 weeks | FDA-approved ✅ |
The real comparison most patients should be making
The honest framing for most people is not “which has the biggest number,” it’s: What does my insurance actually cover? What can my clinician actually prescribe today? What can I afford month over month? What can I stay on long-term? A medication that works at 14% weight loss that you can actually access and stay on beats a medication at 23% weight loss that costs $1,200 a month out of pocket or isn’t available for another 18 months.
Should You Wait for CagriSema or Consider an Approved GLP-1 Now?
Short answer
If you want treatment in the next 30 to 90 days, waiting another 6 to 18 months for CagriSema is a real cost. If you’re not in a hurry or specifically want to track the approval, “wait and watch” is reasonable. Here’s a clean decision framework based on your current situation.
| Your situation | What CagriSema’s status means for you | What to consider |
|---|---|---|
| Not on any GLP-1 yet, considering one | Waiting 6–18 months means losing 6–18 months of potential progress. CagriSema may or may not be the right fit when it arrives. | Talk to a licensed clinician about an FDA-approved option (Zepbound, Wegovy, or Foundayo). You can re-evaluate later if CagriSema makes sense. |
| Currently on Wegovy (semaglutide) | CagriSema would add cagrilintide to your current mechanism. REDEFINE 1 suggests an additional ~7 percentage points of weight loss vs semaglutide alone (efficacy estimand). | If Wegovy is working, covered, and tolerated, discuss staying the course with your clinician and re-evaluate after the FDA decision. |
| Currently on Zepbound (tirzepatide) | REDEFINE 4 suggests Zepbound currently outperforms CagriSema on weight loss. CagriSema would be a lateral move based on current data. | Discuss staying the course with your clinician unless cost, side effects, or supply becomes an issue. The higher-dose CagriSema trial (data in 2027) could change this. |
| Currently on compounded semaglutide or tirzepatide | CagriSema status doesn't directly affect you, but compounded GLP-1 access remains its own regulatory question. | Re-verify your compounding pharmacy access. Consider transitioning to a verified FDA-approved option if budget allows. |
| Type 2 diabetic considering CagriSema | Novo has not announced a CagriSema T2D FDA filing or decision date. The diabetes path will follow additional REIMAGINE/REDEFINE data. | Don't plan active T2D management around CagriSema. Talk to your clinician about FDA-approved diabetes options (Ozempic, Mounjaro) now. |
| You specifically want to track CagriSema | Bookmark this page. We update it as the regulatory status changes. | Set a calendar reminder for Q4 2026, when the FDA decision is expected. |
Wait and watch makes sense when ALL four are true
- Not actively trying to start treatment in the next 90 days
- Specifically prefer the CagriSema mechanism (GLP-1 plus amylin)
- Comfortable if approval is delayed past Q4 2026
- Comfortable that insurance coverage typically lags the FDA decision
Starting now makes sense when ANY of these is true
- Want to start treatment in the next 30 to 90 days
- At higher health risk and waiting carries real medical cost
- Insurance covers an FDA-approved option now
- Want brand-name, FDA-approved medication only
Ro is a strong fit for FDA-approved-only readers
Ro carries FDA-approved Zepbound® (tirzepatide) and Foundayo™ (orforglipron — Eli Lilly’s FDA-approved oral GLP-1 pill). Ro provides an insurance concierge that handles prior-authorization paperwork and a free GLP-1 Insurance Coverage Checker that tells you whether your plan will cover specific medications before you commit.
Disclosure: The RX Index may earn a commission from Ro links. Ro is not affiliated with Novo Nordisk or CagriSema.
See FDA-approved GLP-1 options on Ro →Ro Body starts at $39 for the first month, then $149/month or as low as $74/month with annual plan paid upfront. Medication cost is separate.
What FDA-Approved Alternatives Are Available Right Now?
While CagriSema sits in FDA review, several FDA-approved GLP-1 and incretin-based medications are already available. The right one depends on your insurance, your condition, whether you prefer an injection or a pill, and what you can afford month over month.
| Option | FDA-approved use | When it might fit you | Note |
|---|---|---|---|
| Zepbound (tirzepatide injection) | Chronic weight management; overweight with comorbidity; moderate-to-severe OSA with obesity | You want the highest-efficacy FDA-approved option available | Currently best-in-class for weight loss on head-to-head data |
| Wegovy pill (oral semaglutide) | Chronic weight management | You want an FDA-approved oral GLP-1 with the semaglutide mechanism | First oral GLP-1 receptor agonist approved for weight management (FDA approved Dec 22, 2025) |
| Foundayo (orforglipron pill) | Chronic weight management | You want an oral FDA-approved option from a different molecular class | FDA approved April 1, 2026; first new molecular entity under FDA's CNPV pilot program |
| Wegovy (semaglutide injection) | Chronic weight management; cardiovascular risk reduction | You want a well-established semaglutide injection | Available as a pen |
| Mounjaro (tirzepatide injection) | Type 2 diabetes | You have type 2 diabetes specifically | Same active ingredient as Zepbound, different approved use |
| Ozempic (semaglutide injection) | Type 2 diabetes | You have type 2 diabetes | Same active ingredient as Wegovy, different approved use |
Have insurance? Check coverage first.
Ro’s free GLP-1 Insurance Coverage Checker tells you which FDA-approved GLP-1s your insurance covers, the PA requirements, and your likely out-of-pocket cost. Free, no appointment required.
Disclosure: The RX Index may earn a commission from Ro links.
Check insurance coverage on Ro →Not sure which GLP-1 fits?
Take our free 60-second matching quiz. It routes you to the medication, provider, and payment path that fits your insurance, diagnosis, and budget — including cash-pay compounded options if that’s what you want.
Find your GLP-1 path — free quiz →How Much Will CagriSema Cost?
Nobody knows yet.
Novo Nordisk has not announced U.S. pricing for CagriSema, and won’t until close to commercial launch. Any “CagriSema price” floating around online today is speculation.
| Pricing element | Current status |
|---|---|
| CagriSema U.S. list price | Not announced |
| FDA-approved label | Not yet published (drug not yet approved) |
| Manufacturer savings card | Not announced |
| Insurance formulary placement | Not available (drug not yet approved) |
| Cash-pay partner pricing | Not announced |
| Telehealth availability post-launch | Not announced |
When CagriSema does become available, your real out-of-pocket cost will depend on:
- Whether your insurance covers it (and whether the FDA-approved label matches your situation)
- Prior authorization rules from your specific plan
- Manufacturer savings cards (Novo typically launches these)
- Cash-pay programs (NovoCare, telehealth partners)
- Pharmacy distribution (whether your local pharmacy has it in stock)
- Supply (the dual-chamber pen may limit availability early)
We’ll update this section with verified pricing as soon as Novo announces it. Bookmark this page if you want to track that.
What Side Effects or Safety Issues Are Known So Far?
Short answer
The most commonly reported side effects across all CagriSema trials have been gastrointestinal — nausea, vomiting, diarrhea, and constipation — almost always mild to moderate, and usually decreasing over time. The full safety profile, including contraindications and warnings, won’t be known until the FDA-approved prescribing information is published.
What we don’t know yet (awaiting FDA label)
- Contraindications: Conditions or other medications that rule out CagriSema use
- Warnings: Specific risks the FDA requires highlighting (boxed warnings, if any)
- Long-term durability: Most trial data is to 84 weeks; longer-term safety isn’t well-characterized
- Pancreatitis, gallbladder, and thyroid signals: Tracked across the GLP-1 class — final labeling will reflect FDA conclusions
- Real-world tolerability: Trial populations are screened; real-world use often surfaces side effects not seen in trials
Self-sourcing is the bigger safety risk
The FDA has specifically warned that unapproved GLP-1 products sold online for weight loss can be counterfeit, contaminated, mislabeled, or improperly dosed. If you’re going to take any GLP-1 medication, get it through an FDA-approved supply chain with a licensed clinician supervising — not from an overseas pharmacy, a research-peptide site, or an unverified “compounding” source.
How We Verified This Page
We verified each fact on this page against primary sources: Novo Nordisk press releases and investor materials, the FDA’s public communications and Drugs@FDA, peer-reviewed publications in The New England Journal of Medicine and Hypertension, ClinicalTrials.gov, and major medical conference proceedings.
| Item | Verified answer | Source | Last checked | What would change this |
|---|---|---|---|---|
| FDA approval status | Not approved | Drugs@FDA; Novo Dec 18, 2025 release | May 22, 2026 | FDA decision |
| NDA filing date | December 18, 2025 | Novo Nordisk press release | May 22, 2026 | N/A — historical |
| Expected U.S. decision window | Q4 2026 | Novo Q1 2026 investor presentation | May 22, 2026 | New Novo guidance, PDUFA confirmation, FDA action |
| REDEFINE 1 results (22.7% efficacy estimand) | Confirmed | NEJM (PubMed 40544433) | May 22, 2026 | New analyses or re-publication |
| REDEFINE 2 results (-13.7% treatment-policy) | Confirmed | NEJM (PubMed 40544432) | May 22, 2026 | New analyses |
| REDEFINE 4 results (23.0% vs 25.5%) | Confirmed | Novo press release Feb 23, 2026 | May 22, 2026 | Full publication of results |
| REIMAGINE 2 results (14.2% / 1.91 pp HbA1c) | Confirmed | Novo REIMAGINE 2 release | May 22, 2026 | Peer-reviewed publication |
| FDA position on cagrilintide compounding | Cannot be compounded under federal law | FDA guidance on unapproved GLP-1 drugs | May 22, 2026 | New FDA guidance |
| High-dose CagriSema phase 3b initiation | Expected Q2 2026 | Novo Q1 2026 investor presentation | May 22, 2026 | Trial enrollment update or delay |
| Ro pricing and product lineup | Ro Body $39 first month; carries Zepbound and Foundayo | Ro weight loss page | May 22, 2026 | Ro pricing or formulary change |
| Specific PDUFA target date | Not publicly confirmed | Public Novo / FDA materials | May 22, 2026 | FDA acceptance letter or Novo disclosure |
| Priority review status | Not publicly confirmed | Public Novo / FDA materials | May 22, 2026 | FDA designation announcement |
| Launch pricing | Not announced | N/A | May 22, 2026 | Post-approval pricing announcement |
| Insurance coverage post-approval | Cannot be confirmed until label and launch | N/A | May 22, 2026 | Payer formulary decisions |
Our update cadence
We re-verify this page monthly until Q4 2026, then weekly during the FDA decision window, then immediately on any material FDA action (acceptance, Complete Response Letter, Advisory Committee meeting, approval, or label publication).
CagriSema FDA Approval Status — Frequently Asked Questions
Is CagriSema FDA approved?
No. CagriSema is not FDA approved or commercially available in the United States as of May 22, 2026.
When will CagriSema be FDA approved?
Novo Nordisk's Q1 2026 investor materials list an expected U.S. FDA decision in Q4 2026 (October through December 2026). This is a decision window, not a guarantee of approval.
What is the CagriSema PDUFA date?
No public PDUFA target date has been confirmed as of May 22, 2026. Novo's current investor materials list a U.S. decision expected in Q4 2026.
When will CagriSema be available?
If approved on the expected Q4 2026 timeline, commercial launch is most likely in late 2026 or early 2027. Real-world availability — including widespread pharmacy stocking and insurance coverage — typically lags the FDA decision because launch, supply, and payer policies are separate steps.
Can I buy CagriSema now?
No legitimate commercial prescription route exists for CagriSema right now because the drug is not FDA approved. If a website offers "CagriSema for sale," treat it as a red flag.
Can CagriSema be compounded?
No. FDA guidance is that cagrilintide cannot be used in pharmacy compounding under federal law. Any "compounded CagriSema" offer is not a legal substitute for an FDA-approved product.
What is CagriSema made of?
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg (the GLP-1 receptor agonist also found in Wegovy and Ozempic).
Is CagriSema a pill?
No. CagriSema is a once-weekly subcutaneous injection delivered via a dual-chamber pen device.
Did CagriSema fail its clinical trial?
CagriSema did not fail the trials that support its FDA submission. It missed a non-inferiority endpoint against Zepbound (tirzepatide) in a separate head-to-head trial (REDEFINE 4) in February 2026 — but it still produced 23% mean weight loss in that trial, which is a strong absolute result.
Is CagriSema better than Wegovy?
In REDEFINE 1, CagriSema produced about 7 percentage points more weight loss than semaglutide alone (the active ingredient in Wegovy) at 68 weeks under the efficacy estimand. CagriSema is not yet approved or available.
Is CagriSema better than Zepbound?
Based on the head-to-head REDEFINE 4 trial, Zepbound (25.5%) produced greater weight loss than CagriSema (23.0%) at 84 weeks under the efficacy estimand. Future higher-dose CagriSema trials may close this gap.
Will insurance cover CagriSema?
Unknown. Insurance coverage cannot be confirmed until after approval, the FDA-approved label, launch, and payer formulary decisions.
How much will CagriSema cost?
Pricing has not been announced. Any current "CagriSema price" claim is speculation until Novo Nordisk announces official U.S. launch pricing.
Is there a clinical trial I can join to get CagriSema?
The major Phase 3 trials (REDEFINE 1, 2, 4; REIMAGINE 2) are closed to new enrollment. REDEFINE 11 is ongoing, and Novo's Q1 2026 investor materials listed initiation of a phase 3b high-dose CagriSema trial as expected in Q2 2026. Check ClinicalTrials.gov for current enrollment status.
What should I do if I see CagriSema for sale online right now?
Don't buy it. Verify drug approval status on Drugs@FDA (accessdata.fda.gov). If you want medical weight-loss treatment now, talk to a licensed clinician about FDA-approved options.
Will CagriSema be approved for type 2 diabetes?
Not in the current submission. Novo's current FDA application is for chronic weight management only. Novo has said it will approach authorities about the type 2 diabetes regulatory pathway after additional REIMAGINE 1 and REDEFINE 3 data.
What's the safest next step if I want treatment now?
Talk to a licensed clinician about FDA-approved GLP-1 options. If you want a fast way to see which approved options might fit your situation — based on your insurance, your weight, and your timeline — take our free 60-second matching quiz at therxindex.com/find-my-path.
The Bottom Line
- →CagriSema is not FDA approved.
- →The FDA decision is expected in Q4 2026.
- →Launch is most likely late 2026 or early 2027. Insurance coverage typically follows later.
- →A "compounded CagriSema" is not a legal workaround.
- →While the trial data is strong on weight loss, Zepbound currently outperforms CagriSema on head-to-head efficacy.
- →If you can comfortably wait another 12 to 24 months and specifically want CagriSema's mechanism — bookmark this page. We update it when the regulatory status materially changes.
If you’d rather not wait that long, talk to a licensed clinician about FDA-approved options now. Zepbound, Foundayo, Wegovy pill, and Wegovy injection are all real, approved, and accessible today. Ro is one of the most straightforward ways to get started if you want help with insurance — they handle the prior-authorization paperwork and offer a free coverage checker so you know what you’ll actually pay before you commit.
Not sure which GLP-1 program is right for you?
Take our free 60-second matching quiz. Four questions, one personalized action plan, no email gate.
Already decided you want an FDA-approved option?
Ro Body starts at $39 for the first month, then $149/month or as low as $74/month with annual plan paid upfront. Medication cost is separate.
Disclosure: The RX Index may earn a commission from Ro links.